Cationic Lipids for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposomal delivery systems face challenges in achieving sufficient cell culture or in vivo stability and efficient release of encapsulated materials to target cells, with a need for improved pharmacokinetic properties and reduced toxicity for delivering nucleic acids to various cell types and tissues.
Innovation Solution
Development of a novel class of cationic lipid compounds, specifically designed for liposomal-based nanoparticles, which enhance transfection efficiency, cellular uptake, and intracellular release of nucleic acids, characterized by enhanced pharmacokinetic properties and biodistribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current liposomal delivery systems are used, then nucleic acid delivery is achieved, but transfection efficiency and cellular uptake are insufficient
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by changing parameters such as the hydrocarbon chain length (C16-C24), the presence of double bonds at specific positions, and the substituent groups on the nitrogen atom. These parameter changes in the lipid structure enhance transfection efficiency while maintaining delivery effectiveness. For example, compounds with specific chain lengths and unsaturation patterns show improved cellular uptake compared to conventional lipids.
Solution Approach 2:
The invention creates composite lipid structures combining cationic lipid head groups with specific hydrocarbon chains and substituent groups. These composite structures integrate multiple functional elements: the cationic head for nucleic acid binding, the hydrocarbon chain for membrane interaction, and substituents for enhanced stability and uptake. This composite approach resolves the contradiction by achieving both high transfection efficiency and reliable delivery.
2Productivity
If liposomal delivery systems are used, then nucleic acid encapsulation is achieved, but intracellular release is inefficient
Solution Approach 1:
The patent alters lipid parameters including the introduction of double bonds at specific positions (e.g., Δ9, Δ12) and variation of chain length to optimize intracellular release. These parameter changes enable the lipids to better interact with cellular membranes and facilitate endosomal escape, improving release efficiency while ensuring complete delivery of the nucleic acid payload.
Solution Approach 2:
The cationic lipids act as intermediaries that bridge the extracellular nucleic acid and the intracellular target. The specific structural features of these lipids enable them to mediate endosomal disruption and cytosolic release, resolving the contradiction between efficient encapsulation and efficient release by providing a controlled transition pathway.
3Object-affected harmful factors
If conventional liposomal systems are used, then delivery is achieved, but toxicity is reduced
Solution Approach 1:
The patent optimizes lipid parameters such as chain length (C16-C24), degree of unsaturation, and head group composition to reduce toxicity. These parameter changes result in lipids that are less cytotoxic while maintaining or improving delivery efficiency. For example, specific chain lengths and substituent patterns reduce membrane disruption toxicity while preserving transfection capability.
4Reliability
If current delivery systems are used, then nucleic acid delivery is achieved, but pharmacokinetic properties are insufficient
Solution Approach 1:
The patent modifies lipid parameters including molecular weight, hydrophobicity (through chain length and unsaturation), and charge density to improve pharmacokinetic properties. These changes enhance circulation stability, cellular uptake, and tissue distribution while maintaining effective delivery performance. The optimized lipids show improved pharmacokinetic profiles compared to conventional systems.
Data Source
AI summary
The compounds disclosed herein compound of Formula (I), substructures thereof, and pharmaceutically acceptable salts thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.